Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of subcutaneous efgartigimod PH20 in CIDP
jRCT2051200151Phase 2Completed
- Sponsor
- argenx
- Start
- Mar 2021
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Therapeutic Enzymes → Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial of efgartigimod alfa + hyaluronidase-qvfc in chronic inflammatory demyelinating polyneuropathy (CIDP) (3 arms), sponsored by argenx. Primary endpoints: Stage A: Percentage of patients with confirmed evidence of clinical improvement (ECI) and Stage B: Time to first adjusted INCAT deterioration compared to Stage B baseline. Started Mar 2021; status: completed.
02
Drugs
efgartigimod alfa + hyaluronidase-qvfc
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on jRCT2051200151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051200151.